Sol-Gel Technologies Ltd. (SLGL)

NASDAQ: SLGL · Real-Time Price · USD
0.7600
-0.0910 (-10.69%)
Apr 30, 2025, 4:00 PM EDT - Market closed
Market Cap 21.17M
Revenue (ttm) 11.71M
Net Income (ttm) -9.57M
Shares Out 27.86M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 80,542
Open 0.7000
Previous Close 0.8510
Day's Range 0.7000 - 0.7000
52-Week Range 0.3340 - 1.6500
Beta 1.24
Analysts Strong Buy
Price Target 5.00 (+557.9%)
Earnings Date May 19, 2025

About SLGL

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hype... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 23, 2018
Employees 36
Stock Exchange NASDAQ
Ticker Symbol SLGL
Full Company Profile

Financial Performance

In 2023, Sol-Gel Technologies's revenue was $1.55 million, a decrease of -59.98% compared to the previous year's $3.88 million. Losses were -$27.24 million, 82.5% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SLGL stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 557.90% from the latest price.

Price Target
$5.0
(557.90% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Sol-Gel to receive $16 million during 2025 Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial SGT-610 Ph...

13 days ago - GlobeNewsWire

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

This detailed market intelligence publication offers valuable insights into the innovative technologies, competitive landscape, and emerging opportunities that are reshaping the global surface enginee...

23 days ago - GlobeNewsWire

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 pr...

5 months ago - GlobeNewsWire

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with ov...

9 months ago - GlobeNewsWire

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with ov...

9 months ago - GlobeNewsWire

Sol-Gel Technologies Announces Management Realignment

NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Pha...

10 months ago - GlobeNewsWire

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Ho...

1 year ago - GlobeNewsWire

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phas...

1 year ago - GlobeNewsWire

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Pha...

1 year ago - GlobeNewsWire

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 N...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for...

1 year ago - GlobeNewsWire

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients wi...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for...

1 year ago - GlobeNewsWire

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

NESS ZIONA, Israel & MONTREAL--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), an Israel-based dermatology company and Searchlight Pharma Inc. (“Searchlight”), a private Canadi...

2 years ago - Business Wire

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched i...

2 years ago - GlobeNewsWire

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i...

2 years ago - GlobeNewsWire

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i...

2 years ago - GlobeNewsWire

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two inn...

2 years ago - GlobeNewsWire

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) --  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products...

2 years ago - GlobeNewsWire

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

2 years ago - GlobeNewsWire

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

2 years ago - GlobeNewsWire

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

2 years ago - GlobeNewsWire

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, May 13, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gene...

3 years ago - GlobeNewsWire